Home › Malattie autoimmuni › North Carolina › Durham
Studi clinici su Malattie autoimmuni a Durham, NC
15 studi su Malattie autoimmuni cercano partecipanti presso sedi a Durham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Environmental Risk Factors for the Anti-synthetase Syndrome
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- NIEHS Clinical Research Unit (CRU), Research Triangle Park · a 7 mi di distanza
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Duke University Hospital, Durham
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
In reclutamentoFase 2/3
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill · a 10 mi di distanza
Daratumumab in Primary Antiphospholipid Syndrome
In reclutamentoFase 1/2
- Duke University, Durham
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
In reclutamentoFase 1
- Duke University Medical Center, Durham
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Duke University Hospital, Durham
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
In reclutamentoFase 3
- GSK Investigational Site, Durham
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
In reclutamentoFase 1/2
- UNC Chapel Hill, Chapel Hill · a 10 mi di distanza
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
In reclutamentoFase 2/3
- Duke University, Durham
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
In reclutamentoFase 3
- Duke University Medical Center, Durham
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
In reclutamentoFase 3
- Site Number - 1013, Durham
- Site Number - 1020, Chapel Hill · a 10 mi di distanza
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
In reclutamentoFase 1
- Duke University, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi di distanza
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
In reclutamentoFase 1
- Duke University Health System, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Duke University, Durham
Studi su Malattie autoimmuni in altre città
- Houston, TX21 studi
- Washington, DC19 studi
- New York City, NY19 studi
- Philadelphia, PA16 studi
- Boston, MA13 studi
- Los Angeles, CA12 studi
- Chicago, IL12 studi
- Dallas, TX9 studi
- Cleveland, OH8 studi
- Milwaukee, WI8 studi
- Atlanta, GA8 studi
- Portland, OR8 studi
Altri studi a Durham
- Cancro al seno63 studi
- Cancro (tutti i tipi)58 studi
- Cancro del polmone non a piccole cellule39 studi
- Mieloma multiplo37 studi
- Cancro metastatico33 studi
- Leucemia mieloide acuta33 studi
- Cancro ai polmoni32 studi
- Cancro alla prostata32 studi
- Cancro colorettale28 studi
- Leucemia linfatica cronica27 studi
- Cancro ovarico27 studi
- Insufficienza cardiaca26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.